Daphne Quimi, Director at Amylyx Pharmaceuticals, Inc. (AMLX), bought 5,000 shares at $1.89 ($9K) on 2024-05-14, disclosed to the SEC on 2024-05-16.
Open-market purchase of $9k AMLX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.89 | 2,750 | $5K | 55.0% |
| 2 | $1.89 | 2,250 | $4K | 45.0% |
| Total | $1.89 avg | 5,000 | $9K | 100% |
| Filing → |
| FOLD | SELL | 2022-09-06 | $50K | — | Filing → |
| FOLD | SELL | 2022-08-09 | $70K | — | Filing → |
| FOLD | SELL | 2022-06-21 | $40K | — | Filing → |